AbbVie’s Q2 2026 earnings show $16.99 billion in net revenues (+10.2%), record Skyrizi and Rinvoq growth, a $10.9 billion Apogee Therapeutics acquisition, and updated full-year adjusted EPS guidance.
AbbVie and Apogee Therapeutics have announced a definitive $10.9 billion acquisition agreement. The transaction enhances AbbVie’s global immunology portfolio by adding advanced assets like zumilokibart (APG777) for atopic dermatitis and APG273 for asthma.
Pharmaceutical titan AbbVie is in advanced discussions to purchase anti-inflammatory biotech developer Apogee Therapeutics for $10.9 billion in cash, marking its most significant bolt-on transaction since 2019.
AbbVie’s DECNUPAZ FDA approval provides a critical therapeutic lifeline for adult patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This ultra-rare and highly aggressive [Read More…]
AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
AbbVie presented late-breaking Phase 2 data at SGO 2026 showing that Mirvetuximab Soravtansine PSOC treatment combined with carboplatin achieved a 62.7% response rate in FRα-high patients, offering a new hope for platinum-sensitive recurrence.
AbbVie reports promising Phase 1 MAD results for ABBV-295, a once-weekly injectable amylin analog showing meaningful weight loss and strong tolerability positioning it as a differentiated entrant in the growing cardiometabolic obesity pipeline.
In the Phase 3 AFFIRM study, SKYRIZI (risankizumab) achieved superiority in co-primary endpoints of clinical remission and endoscopic response at week 12 for subcutaneous induction in patients with Crohn’s disease.
On February 20, 2026, the U.S. FDA approved the combination of Venclexta (venetoclax) and acalabrutinib for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This landmark decision establishes the first and only all-oral, fixed-duration (time-limited) regimen for previously untreated patients, offering a significant alternative to continuous therapy or chemoimmunotherapy
AbbVie and Genmab have announced significant topline results from the pivotal Phase 3 EPCORE® DLBCL-1 trial. The study marks a clinical milestone as the first Phase 3 trial to demonstrate a statistically significant improvement in progression-free survival (PFS) for a CD3xCD20 bispecific antibody monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
